TargetBeta
DDC
dopa decarboxylase · also AADC · Decarboxylases
2 programs in company-led studies act on DDC, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Carbidoparule | Novartis | phase 4 | 250 running | – | ChEMBL |
| benserazide, levodopa drug combinationrule | Bial - Portela C | phase 1 | 30 running | – | NCIt |
Conditions their studies are in
- Parkinson Disease, 2 programs
- Attention Deficit Disorder with Hyperactivity, 1 program
- Disruptive, Impulse Control, and Conduct Disorders, 1 program
- Dyskinesias, 1 program
- Fibromyalgia, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.